Biopharma
By
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound and Mounjaro
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
Can a $10 Billion Pipeline Opportunity Help Novartis Outrun Its Entresto Patent Cliff After a $5.94 Billion Profit Beat?
Key Highlights A Landmark Quarter Reinforcing Confidence in Novartis’ Growth Trajectory Novartis’ second-quarter results send an encouraging signal…
Approved Two Months Early, Can GSK’s Jideytro Become the Blueprint for Faster Breakthrough Therapies in NSCLC?
Key Highlights A Landmark Approval Reflecting the Strength of GSK’s Oncology Push GSK’s announcement that the FDA has…
Can Novo Nordisk’s Lawsuit Against Eli Lilly Push the $100 Billion GLP-1 Market Toward More Transparent, Evidence-Based Advertising?
Key Highlights A Landmark Legal Moment Reinforcing Standards in Patient-Facing Advertising Novo Nordisk’s decision to formally challenge Eli…
Roche’s Gazyva Wins Second FDA Priority Review in Months — Is Obinutuzumab Becoming Nephrology’s Next Blockbuster?
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement that the FDA…
Can Sanofi’s Twin Lawsuits Against Pfizer and Moderna Reopen the Bill for $140 Billion-Plus in COVID Vaccine Revenue?
Key Highlights Two Companies, One Shared Technology Dispute Sanofi’s complaints, filed as Translate Bio Inc v. Pfizer Inc…
Pfizer’s $10 Billion Innovent Alliance: Is China Now the Epicenter of Next-Gen Cancer Drug Discovery?
Key Highlights A Broad Multidrug Alliance Built for Scale The agreement spans up to 12 programs, eight originating…
J&J’s $1 Billion Firefly Bio Buy: Has Big Pharma Finally Found a Way to Drug the ‘Undruggable’ KRAS?
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
Can a Single Injection Change Everything? Novartis’s Itvisma Wins EU Approval for Broader SMA Population
Key Highlights Closing a Long-Standing Treatment Gap Itvisma’s approval extends gene replacement therapy to an SMA population that…
Can Novartis’s Up to $1.5 Billion Acquisition of Myricx Bio Unlock a New Generation of Cancer-Fighting Antibody-Drug Conjugates?
Key Highlights A Landmark Exit for Early-Stage Science Brandon Capital’s exit from Myricx Bio represents one of its…
Can Novo Nordisk’s Newly EU-Approved Wegovy Pill Make Weight Loss Treatment as Simple as Taking a Daily Tablet for Millions Across Europe?
Key Highlights A Landmark Shift From Injection to Tablet The European Commission’s authorization marks the first time a…
Is Eli Lilly’s Reported $2 Billion Pursuit of AtaiBeckley About to Redefine the Future of Psychedelic Medicine?
Key Highlights A Premium Bet on Psychedelic Innovation Eli Lilly is negotiating a takeover of AtaiBeckley at a…
Can Sanofi SA’s $1.2 Billion AI-Driven Autoimmune Alliance with Kali Therapeutics Inc Unlock Next-Gen Tri-Specific Antibody Therapies and Disrupt Immunology Markets?
Key Highlights: AI-Powered Biologics Platforms Accelerate Next-Gen Antibody DiscoverySanofi SA’s licensing agreement with Kali Therapeutics Inc highlights the…
Can Eli Lilly and Company’s “Triple-G” AI-Enabled Next-Gen Drug Deliver 15%+ Weight Loss and Redefine the $100B Obesity-Diabetes Market Dominated by Novo Nordisk A/S?
Key Highlights: AI-Driven Clinical Design Unlocks Superior Metabolic OutcomesEli Lilly and Company’s late-stage trial results for retatrutide highlight…
Can Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
How Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
Strategic Industry Analysis: What the Biggest Biopharma Deals of 2025 Reveal About the Future of Drug Innovation
The global biopharmaceutical industry experienced a powerful wave of strategic dealmaking in 2025 as major pharmaceutical companies accelerated…
EU Regulators Back CAMCEVI: A Key Step Toward Expanding Prostate Cancer Treatment Options
Foresee Pharmaceuticals has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…
